2-((2-甲氧基苯基)氨基)乙酸 | 94800-23-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-((2-甲氧基苯基)氨基)乙酸
• 英文名称: 2-((2-Methoxyphenyl)amino)acetic acid
• 英文别名: 2-(2-methoxyanilino)acetic acid
• CAS: 94800-23-4
• 化学式: C₉H₁₁NO₃
• mdl: MFCD00504580
• 分子量: 181.19
• InChiKey: DRMOCHGNKTXIBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Lipid probes and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10168342B2

  公开（公告）日：2019-01-01

  Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

  披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外，还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
• [EN] O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DEO-GLCNAC TRANSFÉRASE (OGT) ET UTILISATIONS DE CEUX-CI
  申请人：HARVARD COLLEGE

  公开号：WO2016004180A1

  公开（公告）日：2016-01-07

  The present invention provides inhibitors of O-GlcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e.g., cancers), autoimmune diseases, and inflammatory diseases.

  本发明提供了O-葡萄糖基-N-乙酰氨基葡萄糖转移酶的抑制剂。通常，这些抑制剂是喹诺酮-6-磺酰胺。本发明还提供了由此产生的药物组合物及其在糖尿病及其并发症、代谢性疾病、神经退行性疾病、增殖性疾病（例如，癌症）、自身免疫性疾病和炎症性疾病中的使用方法。
• Hydrazide compounds
  申请人：deLong A. Mitchell

  公开号：US20070135499A1

  公开（公告）日：2007-06-14

  Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  提供了具有GPCR脱敏抑制活性的肼基化合物，可用于影响、抑制或减少G蛋白受体激酶的作用。还提供了包括治疗有效量肼基化合物和药用可接受载体的药物组合物。还提供了使用这些化合物和/或组合物影响由GPCR控制或影响的疾病状态或病况的各种方法。还提供了使用这些化合物和/或组合物影响疾病状态或病况，如癌症、骨质疏松症和青光眼等的各种方法。
• SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS
  申请人：Wolf Christian

  公开号：US20070265255A1

  公开（公告）日：2007-11-15

  One aspect of the invention relates to chiral bisoxazolidines and their use in asymmetric catalysis. The chiral bisoxazolidines are a novel class of compounds that is expected to find multiple applications, for example, in asymmetric synthesis. For example, a bisoxazolidine ligand enabled the catalytic enantioselective alkynylation and alkylation of a range of aromatic and aliphatic aldehydes, generating chiral propargylic alcohols and secondary alcohols in high yields and enantiomeric excess.

  该发明的一个方面涉及手性双恶唑啉及其在不对称催化中的应用。这种手性双恶唑啉是一种新型化合物类，预计将在多个领域得到应用，例如在不对称合成中。例如，一种双恶唑啉配体使得对一系列芳香族和脂肪族醛的催化不对称炔基化和烷基化成为可能，产生高产率和对映选择性的手性丙炔醇和二级醇。
• [EN] FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO<br/>[FR] AGENTS THÉRAPEUTIQUES ACTIVÉS PAR FAP, ET UTILISATIONS ASSOCIÉES
  申请人：TUFTS COLLEGE

  公开号：WO2015192123A1

  公开（公告）日：2015-12-17

  Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP- expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

  本文披露了细胞毒性蒽环类似物（如阿霉素）和其他治疗剂的前药，这些前药通过成纤维细胞激活蛋白（FAP）选择性地被切割和激活。这些前药可用于将细胞毒性和其他药物靶向输送至表达FAP的组织，包括癌症（如实体肿瘤）。还提供了包含这些前药的药物化合物，以及使用这些前药治疗由FAP上调引起的疾病的方法，例如癌症、纤维化和炎症。